Uncover key drivers, emerging technologies, and competitive movements shaping the calcitonin gene-related peptide receptor antagonist market from 2026–2035 with trusted insights from The Business Research Company
What long-term size projections exist for the Calcitonin Gene-Related Peptide Receptor Antagonist Market covering 2026–2035?
The calcitonin gene-related peptide receptor antagonist market size has experienced rapid expansion in recent years. It is projected to grow from $2.3 billion in 2025 to $2.55 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.2%. The historical growth can be attributed to the limited availability of targeted migraine therapies, a reliance on traditional painkillers, increasing awareness of migraine conditions, a rise in hospital and clinic-based treatments, and early research on cgrp pathways.
The calcitonin gene-related peptide receptor antagonist market size is anticipated to expand significantly in the coming years. Its value is projected to reach $3.85 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.9%. This growth during the forecast period is attributable to the development of novel small molecule antagonists, the expansion of peptide-based CGRP therapies, increasing adoption of homecare treatments, rising pharmaceutical investments in migraine therapies, and a growing patient preference for medications with fewer side effects. Major trends expected in this period include the rising prevalence of migraines and cluster headaches, increasing adoption of targeted CGRP therapies, growth in homecare and outpatient treatment settings, the expansion of monoclonal antibody-based therapies, and an enhanced focus on patient-centric pain management.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25715&type=smp
Which Drivers Are Impacting The Competitive Landscape Of The Calcitonin Gene-Related Peptide Receptor Antagonist Market?
The rising occurrence of migraine is projected to fuel the expansion of the calcitonin gene-related peptide receptor antagonist market moving forward. Migraine is defined as an intense headache often causing throbbing pain, typically on one side of the head. This increase in migraine prevalence is largely attributed to heightened exposure to chronic stress, which disrupts neurological pathways and elevates the likelihood of frequent and severe migraine attacks. Calcitonin gene-related peptide receptor antagonists work by blocking CGRP, a protein that dilates blood vessels and transmits pain signals during a migraine episode, thereby reducing headache pain and other associated symptoms. For example, a report published in December 2025 by the National Center for Biotechnology Information (NCBI), a division of the US-based National Library of Medicine (NLM), revealed that an estimated 2.9 billion people worldwide were affected by headache disorders in 2023, with migraine alone accounting for approximately 487.5 cases per 100,000 population. Thus, the increasing prevalence of migraine is indeed driving the growth of the calcitonin gene-related peptide receptor antagonist market.
What Segments Are Identified Within The Structure Of The Calcitonin Gene-Related Peptide Receptor Antagonist Market?
The calcitonin gene-related peptide receptor antagonist market covered in this report is segmented –
1) By Type: Small Molecule Antagonists, Monoclonal Antibodies, Peptide-Based Antagonists
2) By Drug Type: Zavegepant, Ubrogepant, Olcegepant, Telcegepant, Rimegepant, Other Drug Types
3) By Application: Migraine Treatment, Pain Management, Cardiovascular Conditions, Bone Disorders
4) By End-Users: Hospitals, Clinics, Homecare Settings, Pharmaceutical Companies
Subsegments:
1) By Small Molecule Antagonists: Oral Small Molecule Antagonists, Intranasal Small Molecule Antagonists, Injectable Small Molecule Antagonists
2) By Monoclonal Antibodies: Erenumab, Fremanezumab, Galcanezumab, Eptinezumab
3) By Peptide-Based Antagonists: CGRP Fragment-Based Antagonists, Peptidomimetic CGRP Antagonists
Which Trends Are Expected To Influence The Calcitonin Gene-Related Peptide Receptor Antagonist Market In The Upcoming Years?
Leading companies within the calcitonin gene-related peptide receptor antagonist market are prioritizing approvals for innovative products, such as oral CGRP receptor antagonists, to enhance the effectiveness of migraine treatment, broaden therapeutic applications, and provide more convenient administration methods. These oral CGRP receptor antagonists are small-molecule medications designed to block CGRP, a protein linked to migraine attacks, thereby helping to prevent migraines. For instance, in April 2023, AbbVie Inc., a US-based biotech company, obtained approval from the U.S. Food and Drug Administration (FDA) for QULIPTA (atogepant) specifically to treat chronic migraine in adults. QULIPTA (atogepant) is an oral, once-daily calcitonin gene-related peptide (CGRP) receptor antagonist initially developed for the preventive treatment of migraine in adults, and is now authorized for both episodic and chronic migraine across the United States. It functions by inhibiting the activity of CGRP, a protein that becomes elevated during migraine attacks and contributes to pain signaling and inflammation in the brain. QULIPTA is offered in 10 mg, 30 mg, and 60 mg tablet strengths, with the 60 mg dose having been specifically evaluated for chronic migraine prevention.
Which Major Firms Are Strengthening Their Position In The Calcitonin Gene-Related Peptide Receptor Antagonist Market?
Major companies operating in the calcitonin gene-related peptide receptor antagonist market are AbbVie Inc, Novartis AG, Eli Lilly and Company, Amgen Inc, Alder BioPharmaceuticals Inc, Satsuma Pharmaceuticals Inc, Allergan plc
Access The Complete Report For Deeper Market Insights:
Which Region Shows The Strongest Potential For Future Expansion In The Calcitonin Gene-Related Peptide Receptor Antagonist Market?
North America was the largest region in the calcitonin gene-related peptide receptor antagonist market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin gene-related peptide receptor antagonist market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Calcitonin Gene-Related Peptide Receptor Antagonist Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25715&type=smp
Browse Through More Reports Similar to the Global Calcitonin Gene-Related Peptide Receptor Antagonist Market 2026, By The Business Research Company
Peptide Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report
Cc Chemokine Receptor Type 5 Market Report 2026
https://www.thebusinessresearchcompany.com/report/cc-chemokine-receptor-type-5-global-market-report
Muscarinic Acetylcholine Receptor Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model